MeSH term
Frequency | Condition_Probility | Cadherins/*genetics | 39 | 41.0 |
*Germ-Line Mutation | 7 | 1.0 |
Humans | 133 | 0.0 |
Alleles | 8 | 0.0 |
Cell Transformation, Neoplastic/genetics | 2 | 0.0 |
Child | 7 | 0.0 |
Child, Preschool | 5 | 0.0 |
*DNA Methylation | 49 | 7.0 |
DNA, Neoplasm/chemistry/genetics | 4 | 3.0 |
Gene Expression Profiling | 3 | 0.0 |
*Gene Expression Regulation, Neoplastic | 6 | 0.0 |
*Gene Silencing | 4 | 2.0 |
*Genes, Tumor Suppressor | 7 | 0.0 |
Infant | 5 | 0.0 |
Polymerase Chain Reaction | 29 | 0.0 |
Promoter Regions (Genetics)/*genetics | 9 | 1.0 |
Research Support, U.S. Gov't, P.H.S. | 25 | 0.0 |
Tumor Cells, Cultured | 16 | 0.0 |
*Tumor Suppressor Proteins | 6 | 0.0 |
Anaphase/physiology | 2 | 25.0 |
Cell Line | 4 | 0.0 |
Chromatids/physiology | 2 | 100.0 |
Cyclin B/metabolism | 8 | 8.0 |
Hela Cells | 9 | 0.0 |
Kinetics | 3 | 0.0 |
Metaphase/physiology | 2 | 18.0 |
Mutation | 13 | 0.0 |
Neoplasm Proteins/metabolism | 2 | 0.0 |
Phenotype | 5 | 0.0 |
Recombinant Fusion Proteins/metabolism | 3 | 0.0 |
Research Support, Non-U.S. Gov't | 96 | 0.0 |
Sequence Deletion | 2 | 0.0 |
Trans-Activation (Genetics) | 2 | 0.0 |
Ubiquitins/metabolism | 4 | 2.0 |
Adult | 43 | 0.0 |
Aged | 36 | 0.0 |
Aged, 80 and over | 19 | 0.0 |
Carcinoma/*genetics/pathology | 2 | 3.0 |
Cell Differentiation | 4 | 0.0 |
Female | 59 | 0.0 |
Male | 49 | 0.0 |
Middle Aged | 46 | 0.0 |
*Promoter Regions (Genetics) | 15 | 0.0 |
Sulfites/pharmacology | 6 | 18.0 |
Genes, BRCA1 | 2 | 1.0 |
Genotype | 7 | 0.0 |
Polymorphism, Genetic | 5 | 0.0 |
Prognosis | 14 | 0.0 |
Survival Rate | 5 | 0.0 |
Variation (Genetics) | 2 | 0.0 |
Animals | 16 | 0.0 |
Cell Cycle/physiology | 2 | 0.0 |
Ligases/genetics/*metabolism | 3 | 6.0 |
Transfection | 5 | 0.0 |
*Ubiquitin-Protein Ligase Complexes | 11 | 14.0 |
Base Sequence | 10 | 0.0 |
DNA Primers | 3 | 0.0 |
Exons | 6 | 0.0 |
Gene Frequency | 7 | 0.0 |
*Polymorphism, Single Nucleotide | 2 | 0.0 |
Cell Cycle Proteins/genetics/*metabolism | 3 | 2.0 |
Cyclin A/metabolism | 4 | 5.0 |
DNA-Binding Proteins/metabolism | 3 | 0.0 |
Ligases/*metabolism | 2 | 2.0 |
Ubiquitin/metabolism | 2 | 0.0 |
Incidence | 2 | 0.0 |
Mutation/genetics | 4 | 0.0 |
Risk Factors | 5 | 0.0 |
Syndrome | 3 | 0.0 |
Breast Neoplasms/*genetics | 9 | 1.0 |
Comparative Study | 11 | 0.0 |
DNA/metabolism | 3 | 0.0 |
DNA Mutational Analysis | 11 | 0.0 |
DNA Primers/chemistry | 6 | 0.0 |
Introns | 4 | 0.0 |
Mutation, Missense | 4 | 0.0 |
Pedigree | 17 | 0.0 |
Prostatic Neoplasms/*genetics | 2 | 1.0 |
Stomach Neoplasms/*genetics | 10 | 8.0 |
Case-Control Studies | 6 | 0.0 |
Colorectal Neoplasms/*genetics | 3 | 1.0 |
Genetic Predisposition to Disease | 7 | 0.0 |
Carcinoma, Lobular/*genetics | 2 | 28.0 |
Genes, Reporter | 2 | 0.0 |
*Polymorphism, Genetic | 4 | 0.0 |
Promoter Regions (Genetics) | 23 | 0.0 |
Adolescent | 9 | 0.0 |
Cadherins/metabolism | 3 | 2.0 |
CpG Islands/*genetics | 9 | 9.0 |
Sex Factors | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 7 | 0.0 |
Tumor Markers, Biological/*genetics/metabolism | 2 | 10.0 |
Breast Neoplasms/*genetics/metabolism | 2 | 1.0 |
CpG Islands | 10 | 3.0 |
Genes, Tumor Suppressor | 14 | 1.0 |
Binding Sites | 2 | 0.0 |
*Carrier Proteins | 2 | 0.0 |
Mitosis/physiology | 4 | 4.0 |
*Saccharomyces cerevisiae Proteins | 9 | 0.0 |
Ubiquitin-Protein Ligases | 8 | 3.0 |
Xenopus laevis | 2 | 0.0 |
Disease-Free Survival | 5 | 0.0 |
Multivariate Analysis | 4 | 0.0 |
*Mutation | 6 | 0.0 |
*Gastrectomy | 2 | 8.0 |
Genetic Counseling | 3 | 1.0 |
Cadherins/*metabolism | 2 | 2.0 |
Fungal Proteins/*genetics | 2 | 1.0 |
Gene Expression Regulation, Neoplastic | 10 | 0.0 |
Family Health | 3 | 0.0 |
Germ-Line Mutation | 7 | 1.0 |
Polymorphism, Single-Stranded Conformational | 9 | 0.0 |
Cadherins/analysis/*genetics | 2 | 50.0 |
DNA, Neoplasm/genetics/metabolism | 2 | 2.0 |
Immunohistochemistry | 10 | 0.0 |
Neoplasm Staging | 11 | 0.0 |
DNA, Neoplasm/analysis | 3 | 0.0 |
Breast Neoplasms/*genetics/pathology | 4 | 1.0 |
Cell Cycle Proteins/metabolism | 3 | 0.0 |
Cloning, Molecular | 3 | 0.0 |
Xenopus | 2 | 0.0 |
Follow-Up Studies | 2 | 0.0 |
Gastrectomy | 2 | 3.0 |
Gastric Mucosa/pathology | 2 | 5.0 |
Genetic Markers/genetics | 2 | 0.0 |
Neoplasm Invasiveness | 5 | 0.0 |
Treatment Outcome | 2 | 0.0 |
Age of Onset | 4 | 0.0 |
Genetic Screening | 3 | 0.0 |
DNA Methylation | 9 | 1.0 |
Down-Regulation | 3 | 0.0 |
Carcinoma, Ductal, Breast/*genetics/pathology | 2 | 7.0 |
*Chromosome Deletion | 2 | 0.0 |
Chromosome Mapping | 4 | 0.0 |
*Chromosomes, Human, Pair 16 | 4 | 1.0 |
Loss of Heterozygosity | 8 | 0.0 |
Lymphatic Metastasis | 2 | 0.0 |
Amino Acid Sequence | 7 | 0.0 |
Anaphase | 2 | 9.0 |
Cell Cycle | 3 | 0.0 |
Cells, Cultured | 2 | 0.0 |
*Conserved Sequence | 2 | 1.0 |
Molecular Sequence Data | 10 | 0.0 |
Rats | 3 | 0.0 |
*Mitosis | 4 | 3.0 |
DNA, Neoplasm/genetics | 5 | 0.0 |
*Loss of Heterozygosity | 2 | 0.0 |
Microsatellite Repeats | 4 | 0.0 |
Polymerase Chain Reaction/methods | 5 | 0.0 |
Stomach Neoplasms/*genetics/metabolism | 3 | 11.0 |
Models, Genetic | 3 | 0.0 |
Stomach Neoplasms/etiology/*genetics | 2 | 33.0 |
Adenocarcinoma/*genetics/pathology | 2 | 2.0 |
CpG Islands/genetics | 3 | 2.0 |
Disease Progression | 3 | 0.0 |
Precancerous Conditions/genetics | 2 | 9.0 |
Gene Silencing | 4 | 1.0 |
Genetic Markers | 10 | 0.0 |
Neoplasms/*genetics | 3 | 1.0 |
Cadherins/*biosynthesis/*genetics | 2 | 50.0 |
Chromosomes, Human, Pair 16 | 2 | 1.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
Cadherins/biosynthesis/*genetics | 3 | 25.0 |
Promoter Regions (Genetics)/genetics | 4 | 0.0 |
Genes, Tumor Suppressor/*physiology | 2 | 1.0 |
Sensitivity and Specificity | 3 | 0.0 |
Genetic Predisposition to Disease/genetics | 4 | 0.0 |
Germ-Line Mutation/*genetics | 4 | 2.0 |
Portugal | 2 | 3.0 |
Trans-Activators/*genetics | 2 | 0.0 |
Microsatellite Repeats/genetics | 4 | 1.0 |
Neoplasm Proteins/*genetics | 5 | 0.0 |
Genes, APC | 3 | 3.0 |
Chromosomes, Human, Pair 16/*genetics | 3 | 3.0 |
Exons/genetics | 4 | 0.0 |
Phosphorylation | 3 | 0.0 |
Protein Binding | 4 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 3 | 0.0 |
Cadherins/*genetics/physiology | 3 | 50.0 |
Genetic Screening/*methods | 2 | 1.0 |
Cell Cycle Proteins/*metabolism | 3 | 0.0 |
Cyclins/metabolism | 2 | 0.0 |
Ubiquitin-Protein Ligase Complexes/*metabolism | 2 | 22.0 |
Cell Cycle/*physiology | 3 | 1.0 |
Mice | 5 | 0.0 |
Mitosis | 2 | 0.0 |
Protein Kinases/metabolism | 3 | 0.0 |
*Schizosaccharomyces pombe Proteins | 2 | 2.0 |
Prostatic Neoplasms/*genetics/pathology | 2 | 2.0 |
DNA Replication/genetics | 2 | 3.0 |
Precancerous Conditions/genetics/pathology | 2 | 11.0 |
Carcinoma, Lobular/*genetics/pathology | 2 | 28.0 |
Gene Deletion | 3 | 0.0 |
Haplotypes | 2 | 0.0 |
Stomach Neoplasms/*genetics/pathology | 3 | 6.0 |
Cadherins/*genetics/metabolism | 3 | 21.0 |
*Genes, APC | 3 | 3.0 |
Proportional Hazards Models | 2 | 0.0 |
Mutation/*genetics | 2 | 0.0 |
Colorectal Neoplasms/*genetics/pathology | 3 | 3.0 |
Point Mutation | 3 | 0.0 |
*Polymorphism, Single-Stranded Conformational | 2 | 1.0 |
*Chromosome Mapping | 2 | 0.0 |
Hamsters | 2 | 0.0 |
Linkage (Genetics) | 2 | 0.0 |
Herpesvirus 4, Human/genetics | 2 | 2.0 |
Ubiquitin-Protein Ligase Complexes/genetics/*metabolism | 3 | 50.0 |
Protein Conformation | 2 | 0.0 |
Asian Continental Ancestry Group/*genetics | 2 | 0.0 |
China | 2 | 0.0 |
*Gene Deletion | 2 | 0.0 |
Heterozygote | 4 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Time Factors | 4 | 0.0 |
*Cell Transformation, Neoplastic | 2 | 0.0 |
Cell Line, Tumor | 3 | 0.0 |
DNA/chemistry | 2 | 0.0 |
*Acid Anhydride Hydrolases | 2 | 0.0 |
Cadherins/genetics | 7 | 12.0 |
Caspases/genetics | 2 | 8.0 |
O(6)-Methylguanine-DNA Methyltransferase/genetics | 6 | 21.0 |
Protein p16/genetics | 5 | 5.0 |
Cell Division | 2 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Neoplasm Proteins/genetics | 5 | 1.0 |
Carcinoma, Non-Small-Cell Lung/*genetics | 2 | 2.0 |
English Abstract | 2 | 0.0 |
Lung Neoplasms/*genetics | 2 | 0.0 |
In Vitro | 3 | 0.0 |
Colorectal Neoplasms/genetics/pathology | 2 | 11.0 |
Saccharomyces cerevisiae Proteins/*genetics | 2 | 12.0 |
*Genetic Predisposition to Disease | 2 | 0.0 |
*Mutation, Missense | 2 | 0.0 |
Methylation | 3 | 0.0 |
Neoplasm Metastasis | 2 | 0.0 |
Receptors, Retinoic Acid/genetics | 4 | 4.0 |
Cell Cycle Proteins/genetics | 2 | 2.0 |
Transcription Factors/genetics | 2 | 0.0 |
p14ARF Protein/genetics | 3 | 14.0 |
Isoenzymes/genetics | 2 | 0.0 |
Microsatellite Repeats/*genetics | 2 | 0.0 |
Saccharomyces cerevisiae Proteins/genetics | 2 | 5.0 |
Adenomatous Polyposis Coli Protein/genetics | 2 | 12.0 |
Odds Ratio | 2 | 0.0 |
